The PMN 34 Month and 90 Week Cycles Are Here!It is interesting to note that PMN has experienced a very consistent 34 month cycle. If we look back 34 months, we have the Jan 2018 high at $0.73. 34 months prior to that peak, PMN recorded it's major restructuring bottomed at $0.025. 34 months prior to that we had a double top in 2012 at $0.56 and $0.64. 34 months prior to that we had a major peak at $1.35 and the high of the year in 2009. So the cycle is once again completing. It is also important to recognize that today's low is retest of the March 2020 low. If that wasn't enough we are also completing a 90 week cycle. It has been rarely off by more than a few weeks dating all the way the high in 2007. It is remarkable that these two cycles are phasing together with the Aducanumab/Biogen news and what certainly appear to be capitulation, as expressed not only on this blog but also the stock price. Demark analysis of the stock movement on daily, weekly and monthly charts exhibit exhaustion to the downside. Momentum analysis highlights positive divergences [see RSI], often seen at important turning points. I appreciate the lack of confidence in management and the fact that they have proven time and again that they can't deliver a suitable partnership or raise the kind of capital needed to move PMN310 to the clinicals. That said, the science is truly remarkable and desperately in need. The companies current valuation is absurd given it's promise. A reversal is at hand in my opinion.